Evidence map›Paper›PMID 31581433›Full record

ArticleMolecules (Basel, Switzerland)2019

Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor.

Shakiru O Alapafuja, Spyros P Nikas, Thanh C Ho, Fei Tong, Othman Benchama, Alexandros Makriyannis

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Synthesis of Functionalized Cannabilactones.Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shakiru O AlapafujaCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. s.alapafuja@northeastern.edu.
Spyros P NikasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. s.nikas@northeastern.edu.ORCID 0000-0001-5052-5292
Thanh C HoCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. t.ho@northeastern.edu.ORCID 0000-0001-6880-7570
Fei TongCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. tong.f@husky.neu.edu.
Othman BenchamaCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. othmanb@gmail.com.
Alexandros MakriyannisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. a.makriyannis@northeastern.edu.
Northeastern University · US

Funding

New Modalities for the Treatment of Pain and Drug Abuse-Biochemical CoreP01DA041307 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK · 2017 to 2021
$3.0M
NIDA NIH HHS P01 DA041307NIH HHS DA009158NIH HHS DA041307-01NIH HHS DA045020
6 · The paper itself

Abstract

In earlier work, we reported a novel class of CB2 selective ligands namely cannabilactones. These compounds carry a dimethylheptyl substituent at C3, which is typical for synthetic cannabinoids. In the current study with the focus on the pharmacophoric side chain at C3 we explored the effect of replacing the C1'-

Indexed as

AnimalsCannabinoidsHEK293 CellsHumansLactonesMiceMolecular StructureRatsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Species SpecificityStructure-Activity RelationshipCannabinoidsLactonesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2cannabilactonescannabinoid receptorsCB2 selective ligandsstructure-activity relationship studiessynthesis

Identifiers

PMID31581433
PMCPMC6804212
OpenAlexW2976285964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.